2nd ADC toxicity summit https://storage.pardot.com/448062/1713868707LeQ1wadz/HW240322_46355_2nd_ADC_Toxicity_Summit_brochure_v8.pdf
"Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization within Minutes w
Unique Multimodal MOA & Safety Profile
- Understand the rationale for targeting the SORT1 receptor in cancer
- Discuss the unique toxicity profile of sudocetaxel zendusortide (TH1902), the lead PL from Theratechnologies' SORT1+ Technology ™ platform, that differs substantially fro the safety profile of taxanes, due to the multimodal MOA of the conjugate and the low levels of free circulating docetaxel
- Discuss how this multifaceted MOA with improved safety profile can lead to prolonge regression of disease and enable combinations with ADCs, PDCs and other anti-can therapies
- Discuss the ongoing phase I clinical development of sudocetaxel zendusortide, focus on dose optimization"
So Christian is speaking at this summit this time the focus is toxicity/ safety profile of the drug!
Have they had more human data so far as the issue with the drug and abrupt stop of the clinical trial initially was because of toxicity/safety concerns??